外科理论与实践

外科理论与实践 >

2024 , Vol. 29 >Issue 03: 230 - 235

DOI: https://doi.org/10.16139/j.1007-9610.2024.03.08

论著

血清中PD-L1含量与胃癌病人预后的关系

  • 陈长强 ,
  • 严晓伟 ,
  • 胡皆乐 ,
  • 包皙婷 ,
  • 项明 ,
  • 姜松耀
展开
  • a.上海交通大学医学院附属瑞金医院 检验科，上海 201800
    b.上海交通大学医学院附属瑞金医院 普外科，上海 201800
姜松耀，E-mail：jiangsydr@163.com

收稿日期: 2023-06-08

  网络出版日期: 2024-09-03

收起

Relationship between serum PD-L1 levels and prognosis of gastric cancer patients

  • CHEN Changqiang ,
  • YAN Xiaowei ,
  • HU Jiele ,
  • BAO Xiting ,
  • XIANG Ming ,
  • JIANG Songyao
Expand
  • a. Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China
    b. Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201800, China

Received date: 2023-06-08

  Online published: 2024-09-03

Fold

摘要

目的：分析胃癌病人血清中程序性死亡配体1（programmed death-ligand 1, PD-L1）含量及其与肿瘤分期和预后的关系。方法：收集我院2018年8月至2019年12月60例胃癌病人血清，15例健康成人血清作为对照，通过酶联免疫吸附试验（ELISA）检测血清PD-L1的含量，比较胃癌病人与健康成人血清PD-L1含量的差异，分析胃癌病人血清PD-L1的含量与病期及预后的关系。免疫组织化学检测肿瘤组织内PD-L1的表达情况，并分析其与血清中PD-L1含量的相关性。结果：胃癌组血清中PD-L1的含量明显高于对照组。Ⅲ、Ⅳ期胃癌病人血清PD-L1含量明显高于Ⅰ、Ⅱ期胃癌病人。胃癌病人合并腹膜转移者血清PD-L1含量明显升高，提示预后不良。生存分析显示，血清PD-L1含量高的胃癌病人生存期明显短于低者。检测肿瘤组织标本中PD-L1的表达水平，发现其与血清中PD-L1含量无明显相关性。结论：胃癌病人血清中PD-L1含量高于健康成人。随病期进展逐渐升高。胃癌伴腹膜转移的病人血清中PD-L1升高明显。血清中PD-L1含量与肿瘤组织中的PD-L1表达不相关。

关键词： 胃癌; 程序性死亡配体1; 血清

本文引用格式

陈长强 , 严晓伟 , 胡皆乐 , 包皙婷 , 项明 , 姜松耀 . 血清中PD-L1含量与胃癌病人预后的关系[J]. 外科理论与实践, 2024 , 29(03) : 230 -235 . DOI: 10.16139/j.1007-9610.2024.03.08

Abstract

Objective To analyze the serum PD-L1 levels of gastric cancer patients and its relationship with tumor stage and prognosis. Methods Serum of sixty patients with pathological diagnosis of gastric cancer in our hospital from August 2018 to December 2019 were collected, and the serum of 15 healthy adults as a control. The serum PD-L1 levels was measured by enzyme linked immunosorbent assay(ELISA). The serum PD-L1 levels between gastric cancer patients and healthy adults were compared.The relationship between the serum PD-L1 levels and prognosis of gastric cancer patients with different stages was analyzed. Finally, the PD-L1 expression in tumor tissues was detected by immunohistochemical staining, and its correlation with serum PD-L1 levels was analyzed. Results The serum PD-L1 levels of gastric cancer group was significantly higher than that of the control group. The serum PD-L1 levels in patients with stage Ⅲ and Ⅳ gastric cancer was significantly higher than that in stage Ⅰ and Ⅱ. The serum PD-L1 levels in gastric cancer patients with peritoneal metastasis was significantly elevated, indicating poor prognosis. Kaplan-Meier survival analysis showed that the survival time of gastric cancer patients with higher level of serum PD-L1 was shorter than those with lower ones. We further evaluated the PD-L1 expression in tumor tissues. There was no significant correlation between the serum PD-L1 levels and that in tumor tissues. Conclusions The serum PD-L1 levels of gastric cancer patients was higher than that of healthy adults, and which gradually increased with the progression of the disease. Gastric cancer patients with peritoneal metastasis had a much higher serum PD-L1 levels, and there was no significant correlation between serum PD-L1 levels and PD-L1 expression in tumor tissues.

Key words： Gastric cancer; Programmed death-ligand 1（PD-L1）; Serum

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] CUNNINGHAM S C, KAMANGAR F, KIM M P, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution[J]. J Gastrointest Surg, 2005, 9(5):718-725.
[3] BANG Y J, VAN CUTSEM E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697.
[4] DONG H, ZHU G, TAMADA K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion[J]. Nat Med, 1999, 5(12):1365-1369.
[5] FREEMAN G J, LONG A J, IWAI Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192(7):1027-1034.
[6] ZOU W, CHEN L. Inhibitory B7-family molecules in the tumour microenvironment[J]. Nat Rev Immunol, 2008, 8(6):467-477.
[7] CURIEL T J, WEI S, DONG H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity[J]. Nat Med, 2003, 9(5):562-567.
[8] BRAHMER J, RECKAMP K L, BAAS P, et al. Ni-volumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
[9] LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1):23-34.
[10] B?GER C, BEHRENS H M, MATHIAK M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients[J]. Oncotarget, 2016, 7(17):24269-24283.
[11] CHEN Y, WANG Q, SHI B, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines[J]. Cytokine, 2011, 56(2):231-238.
[12] GU L, CHEN M, GUO D, et al. PD-L1 and gastric cancer prognosis: systematic review and meta-analysis[J]. PLoS one, 2017, 12(8):e0182692.
[13] QING Y, LI Q, REN T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer[J]. Drug Des Devel Ther, 2015, 9:901-909.
[14] 王玉丰, 姚南, 王军, 等. PD-1和PD-L1与胃癌患者预后相关性的Meta分析[J]. 肿瘤防治研究, 2020, 47(5):346-352.
  WANG Y F, YAO N, WANG J, et al. Meta analysis of the correlation between PD-1 and PD-L1 with the prognosis of gastric cancer patients[J]. Cancer Res Prev Treat, 2020, 47(5):346-352.
[15] ZHENG Z, BU Z, LIU X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[J]. Chin J Cancer Res, 2014, 26(1):104-111.
[16] FRIGOLA X, INMAN B A, KRCO C J, et al. Soluble B7-H1: differences in production between dendritic cells and T cells[J]. Immunol Lett, 2012, 142(1-2):78-82.
[17] AMATATSU M, ARIGAMI T, UENOSONO Y, et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer[J]. Cancer Sci, 2018, 109(3):814-820.
[18] BORGHAEI H, PAZ-ARES L, HORN L, et al. Ni-volumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
[19] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550.
Options
文章导航

/

〈 〉